Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

10.17
Delayed Data
As of Oct 23
 -0.22 / -2.12%
Today’s Change
7.41
Today|||52-Week Range
23.11
-25.33%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$345.2M

Company Description

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It's proprietary chemical induction of dimerization technology engineers and controls components of the immune system. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Contact Information

Bellicum Pharmaceuticals, Inc.
Life Science Plaza
Houston Texas 77030
P:(832) 384-1100
Investor Relations:

Employees

Shareholders

Individual stakeholders33.18%
Other institutional28.26%
Mutual fund holders26.51%

Top Executives

Richard A. FairPresident, Chief Executive Officer & Director
Alan A. MussoChief Financial Officer & Treasurer
David M. SpencerChief Scientific Officer
Kenneth Ray MoseleySecretary, Senior Vice President & General Counsel
Joseph Howard SenesacVice President-Viral Vector Development